{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-002193","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.175253+00:00","generated_at":"2026-05-23T23:22:40.648209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M","bullets":["Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.","Net loss $5.1M vs $4.5M in FY2023; G&A expenses $16.5M, up from $13.1M.","Completed ~$10M underwritten public offering for expansion of sales operations.","Launched 13 new generic drugs; received Health Canada approval for oncology drug NIOPEG.","Published PLpro inhibitor study in J. Med. Chem.; completed mouse model proof-of-concept for K1.1 mRNA."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-002193","json":"https://secwatch.observer/filing/0001683168-25-002193.json","markdown":"https://secwatch.observer/filing/0001683168-25-002193.md","text":"https://secwatch.observer/filing/0001683168-25-002193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825002193/0001683168-25-002193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825002193/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T23:22:40.648209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}